ISSUE 1409
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor, for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the third new oral anticoagulant to be approved for this indication as an alternative to warfarin.1,2
STANDARD TREATMENT — Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulation can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following: heart failure, hypertension, age ≥75 years, diabetes, or prior stroke or transient ischemic attack (CHADS2 score ≥1).3 For many years, the vitamin K antagonist warfarin (Coumadin, and generics) has been the oral anticoagulant of choice for prevention of thromboembolic stroke in patients
... more
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1409a
Electronic, downloadable article - $45